These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 35856212)
21. Cost-effectiveness of influenza vaccination of older adults in the ED setting. Patterson BW; Khare RK; Courtney DM; Lee TA; Kyriacou DN Am J Emerg Med; 2012 Sep; 30(7):1072-9. PubMed ID: 21908140 [TBL] [Abstract][Full Text] [Related]
22. Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older. Maciosek MV; Solberg LI; Coffield AB; Edwards NM; Goodman MJ Am J Prev Med; 2006 Jul; 31(1):72-9. PubMed ID: 16777545 [TBL] [Abstract][Full Text] [Related]
23. The cost-effectiveness of starting 23-valent pneumococcal polysaccharide vaccine and influenza vaccination at 50 vs. 65 years: A comparative modelling study. Ding H; Huang J; Ngai CH; Sun Q; Kwok KO; Wang HH; Chong M; Wong MC Vaccine; 2022 Feb; 40(9):1282-1288. PubMed ID: 35094867 [TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. Jacobs MS; Kaasenbrood F; Postma MJ; van Hulst M; Tieleman RG Europace; 2018 Jan; 20(1):12-18. PubMed ID: 27733465 [TBL] [Abstract][Full Text] [Related]
25. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842 [TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach. Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of Strategies for Offering Influenza Vaccine in the Pediatric Emergency Department. Hart RJ; Stevenson MD; Smith MJ; LaJoie AS; Cross K JAMA Pediatr; 2018 Jan; 172(1):e173879. PubMed ID: 29114729 [TBL] [Abstract][Full Text] [Related]
28. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056 [TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of influenza vaccination during pregnancy in Japan. Hoshi SL; Shono A; Seposo X; Okubo I; Kondo M Vaccine; 2020 Oct; 38(46):7363-7371. PubMed ID: 33020012 [TBL] [Abstract][Full Text] [Related]
30. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China]. Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456 [No Abstract] [Full Text] [Related]
31. A cost-effectiveness analysis of South Africa's seasonal influenza vaccination programme. Edoka I; Kohli-Lynch C; Fraser H; Hofman K; Tempia S; McMorrow M; Ramkrishna W; Lambach P; Hutubessy R; Cohen C Vaccine; 2021 Jan; 39(2):412-422. PubMed ID: 33272702 [TBL] [Abstract][Full Text] [Related]
32. Evaluating the effectiveness and cost-effectiveness of free influenza vaccination policy for older adults in Yinzhou, China: Study protocol of a real-world analyses. Zhang X; Shen P; Liu J; Ji X; Su K; Hu R; Chen C; Fang H; Jin X; Lin H; Sun Y; Yan LL Vaccine; 2023 Jul; 41(34):5045-5052. PubMed ID: 37419850 [TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of Pediatric Influenza Vaccination in The Netherlands. de Boer PT; Nagy L; Dolk FCK; Wilschut JC; Pitman R; Postma MJ Value Health; 2021 Jan; 24(1):19-31. PubMed ID: 33431149 [TBL] [Abstract][Full Text] [Related]
34. [Evaluation of economic outcomes of "hepatitis B vaccine event reported by media" in China, 2013]. Zhang SX; Sun PP; Xia Y Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Aug; 52(8):837-841. PubMed ID: 30107719 [No Abstract] [Full Text] [Related]
35. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Nichol KL Arch Intern Med; 2001 Mar; 161(5):749-59. PubMed ID: 11231710 [TBL] [Abstract][Full Text] [Related]
36. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model. Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174 [TBL] [Abstract][Full Text] [Related]
37. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. Khazeni N; Hutton DW; Garber AM; Owens DK Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760 [TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. Smith KJ; Zimmerman RK; Nowalk MP; Lin CJ J Am Geriatr Soc; 2017 Apr; 65(4):763-768. PubMed ID: 28024090 [TBL] [Abstract][Full Text] [Related]
39. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong. You JHS; Ming WK; Lee CF; Tsang OT; Chan PK Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739 [TBL] [Abstract][Full Text] [Related]
40. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]